Science & Technology – Pheon Therapeutics

Proprietary Technology

Antibody-Drug Conjugates (ADCs) consist of an antibody that is chemically linked to a cytotoxic payload to deliver potent cytotoxic agents directly to cancer cells. The antibody carries the payload to a cancer cell, where it is internalized and then released.

ADCs are rapidly gaining clinical and commercial momentum, with 13 ADCs already approved by the FDA and >100 ADCs in clinical trials.

Pheon Therapeutics has a different approach

The company is addressing key opportunities to extend the benefit of ADCs to more patients through:

1. Novel oncology targets

Multiple wholly-owned first-in-class solid tumor programs with in vivo Proof of Concept.
Lead program aiming for a 2024 IND, with robust preclinical data including in vivo efficacy, NHP safety, and extensive expression profiling in tumors and healthy tissue.
Additional programs under evaluation.

2. Proprietary payloads

Novel payloads to overcome resistance to approved anticancer agents and ADCs containing traditional cytotoxic payloads.
Novel Modes of Action.
Potency not dependent on mitotic index.
Tuneable potency enables purpose-built ADC products pairing the target and indication with an appropriate payload/DAR.

Lead Candidate

PHN-010 is an ADC targeted to an internalizable single-pass transmembrane protein which is highly over-expressed in multiple solid tumors and has low expression in healthy tissues.